Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project
The collaboration, using an aptamer-based approach, will integrate the innovative technology platforms of the three companies, combining Xantos' target discovery expertise and small molecule screening technology, PSF Biotech's protein production and crystallisation capabilities and NascaCell's aptamer technology for target validation and drug discovery. By combining the expertise of the three partners, the consortium called PADDION aims to develop new drugs with the potential to replace or complement established therapies and will receive initial funding by the BioChancePlus program from the German Federal Ministry of Education and Research (BMBF).
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.